- Trials with a EudraCT protocol (80)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
80 result(s) found for: A-not-B error.
Displaying page 1 of 4.
EudraCT Number: 2008-003586-45 | Sponsor Protocol Number: Painscales_Sedation_1 | Start Date*: 2009-09-24 |
Sponsor Name:Department of Anaesthesie, General Intensive Care and Pain Therapy | ||
Full Title: The precision of three pain scales as a function of sedation | ||
Medical condition: This is a patient study in patients with a planned operation under general anaesthesie including healthy or merately ill patients (anaesthesia risk classification ASA 1-3). Pain self assessment as ... | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-024068-16 | Sponsor Protocol Number: LAL-CL01 | Start Date*: 2011-03-08 | |||||||||||||||||||||
Sponsor Name:Synageva Biopharma Corp. | |||||||||||||||||||||||
Full Title: An open label multicenter study to evaluate the safety, tolerability and pharmacokinetics of SBC-102 in adult patients with liver dysfunction due to lysosomal acid lipase deficiency. | |||||||||||||||||||||||
Medical condition: Lysosomal Acid Lipase (LAL) Deficiency is a rare autosomal recessive lipid storage disorder that is caused by deficient activity or absence, of the lysosomal enzyme, LAL. It is an extremely rare di... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) CZ (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-003299-22 | Sponsor Protocol Number: BILA-3514/SCA | Start Date*: 2014-11-18 |
Sponsor Name:TNO.Netherlands Organization for Applied Scientific Research | ||
Full Title: Effects of Single Dose of Bilastine 20mg on Flying Ability in Healthy Volunteers Under Conditions of Simulated Cabin Pressure | ||
Medical condition: Healthy volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-005504-36 | Sponsor Protocol Number: ABNCoV2-03 | Start Date*: 2022-09-19 | |||||||||||
Sponsor Name:Bavarian Nordic A/S | |||||||||||||
Full Title: Evaluation of the Immunogenicity, Safety, and Tolerability of a Single Dose of ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2: a Phase 3 Trial in Two Parts—Randomized, Doubl... | |||||||||||||
Medical condition: COVID-19 disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003340-37 | Sponsor Protocol Number: PJ21069 | Start Date*: 2018-10-30 | |||||||||||
Sponsor Name:Technological University Dublin | |||||||||||||
Full Title: Efficacy and Mechanisms of Low Dose Atropine in the Control of Myopia in Children Trial name: Myopia Outcome Study of Atropine in Children (MOSAIC) | |||||||||||||
Medical condition: Myopia- a refractive error due to a discrepancy between the anatomical axial length and the focal length of the eye. resulting in distant objects appearing blurred | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002481-78 | Sponsor Protocol Number: EBI-EA230-LPS-2014 | Start Date*: 2014-10-07 |
Sponsor Name:Exponential Biotherapies Inc | ||
Full Title: Randomized double blind placebo-controlled clinical safety, tolerability and pharmacokinetic/-dynamic study on the effects of escalating single intravenous doses of EA-230 on the innate immune resp... | ||
Medical condition: Systemic inflammatory respons (SIRS) and associated acute kidney injury (AKI) | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-005600-28 | Sponsor Protocol Number: EBI-CABG | Start Date*: 2016-06-17 |
Sponsor Name:Exponential Biotherapies Inc. | ||
Full Title: Randomized double blind placebo-controlled phase II study on the effects of EA-230 on the innate immune response following on-pump cardiac surgery | ||
Medical condition: Systemic inflammatory respons (SIRS) and associated acute kidney injury (AKI) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-000304-16 | Sponsor Protocol Number: B4Z-UT-S017 | Start Date*: 2021-12-02 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized, Double-blind Comparison of Atomoxetine Hydrochloride and Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents With Autism Spectrum Disorder. | |||||||||||||
Medical condition: Attention-Deficit/Hyperactivity Disorder | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004840-51 | Sponsor Protocol Number: EIP19-NFD-401 | Start Date*: 2019-06-26 | |||||||||||
Sponsor Name:EIP Pharma, Inc. | |||||||||||||
Full Title: A Double-Blind, Placebo-Controlled Two-Period 10-Week Treatment Within-Subject Crossover Study Of Cognitive Effects Of Neflamapimod in Early-Stage Huntington Disease (HD) | |||||||||||||
Medical condition: Early-Stage Huntington Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023044-32 | Sponsor Protocol Number: DCS-fMRIPanik | Start Date*: 2011-08-10 |
Sponsor Name:Charité Universitaetsmedizin Berlin | ||
Full Title: Mechanisms of action in exposure therapy: Decoding the neural basis of fear extinction and its pharmacological modulation in patients with panic disorder | ||
Medical condition: panic disorder and agoraphobia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-004775-13 | Sponsor Protocol Number: SYD-101-001 | Start Date*: 2019-08-02 | |||||||||||
Sponsor Name:Sydnexis, Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Masked, Vehicle-Controlled Study to Assess the Safety and Efficacy of SYD-101 Ophthalmic Solution for the Treatment of Myopia in Children | |||||||||||||
Medical condition: Myopia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Trial now transitioned) AT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000097-26 | Sponsor Protocol Number: TDE-PH-310 | Start Date*: 2012-11-06 | |||||||||||
Sponsor Name:United Therapeutics Corporation | |||||||||||||
Full Title: A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects with Pulmonary Arterial Hypertension Receiving Background Oral... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) AT (Completed) NL (Completed) IT (Completed) SE (Completed) BE (Completed) DK (Completed) GR (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004970-24 | Sponsor Protocol Number: NHL-14 | Start Date*: 2008-01-17 | |||||||||||
Sponsor Name:AGMT - Arbeitsgemeinschaft Medikamentöse Tumortherapie Gemeinnützige GmbH | |||||||||||||
Full Title: Multizentrische Studie über die Cardiotoxizität von R-CHOP (Rituximab, Cyclophosphamid, Doxorubicin, Vincristin und Prednisolon) v. R-COMP (Rituximab, Cyclophosphamid, liposomalem Doxorubicin, Vinc... | |||||||||||||
Medical condition: Diffus großzelliges B-Zell Lymphom | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014568-21 | Sponsor Protocol Number: | Start Date*: 2011-09-07 | |||||||||||
Sponsor Name:NHS Greater Glasgow & Clyde [...] | |||||||||||||
Full Title: VALIDATION OF AN EFFECT-SITE TARGETED PROPOFOL INFUSION FOR ANAESTHESIA IN CHILDREN | |||||||||||||
Medical condition: Children undergoing general anaesthesia | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000157-87 | Sponsor Protocol Number: 2022-03 | Start Date*: 2022-08-23 |
Sponsor Name:Hvidovre Hospital | ||
Full Title: HypoBar I: Delaying intestinal glucose absorption to ameliorate post-bariatric hypoglycaemia. A randomized cross-over clinical trial. | ||
Medical condition: Post-bariatric hypoglycaemia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DK (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2015-000815-42 | Sponsor Protocol Number: HighNxGHR_PK | Start Date*: 2015-04-28 | |||||||||||
Sponsor Name:Rigshospitalet, Copenhagen University Hospitals | |||||||||||||
Full Title: Pharmacokinetics of High-dose Target-controlled Naloxone Infusion. Companion study to: Effect of High-dose Target-controlled Naloxone Infusion on Pain and Hyperalgesia in Patients following Groin-H... | |||||||||||||
Medical condition: Healthy subjects | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004567-36 | Sponsor Protocol Number: MK-3475-240 | Start Date*: 2016-05-13 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240) | |||||||||||||
Medical condition: Hepatocellular Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) DE (Completed) DK (Completed) HU (Completed) FR (Completed) GB (GB - no longer in EU/EEA) PL (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-024584-41 | Sponsor Protocol Number: PR196/10 | Start Date*: 2011-06-30 |
Sponsor Name:Hospital Universitari de Bellvitge | ||
Full Title: Ensayo clínico, multicéntrico, aleatorio y controlado con placebo para evaluar la eficacia de la administración de concentrado de fibrinógeno sobre los requerimientos de derivados sanguíneos en la ... | ||
Medical condition: El trasplante hepático es una situación especial de riesgo de sangrado agudo y grave determinado por la complejidad del procedimiento quirúrgico y por la alteración de la hemostasia y coagulación p... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2009-017063-42 | Sponsor Protocol Number: ML22606 | Start Date*: 2010-12-07 |
Sponsor Name:Roche Romania SRL | ||
Full Title: Biomarkers Impact On the response to Treatment with Erlotinib in first line non-small cell lung Cancer with EGFR activating mutations | ||
Medical condition: Non-small cell lung cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: RO (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-002877-23 | Sponsor Protocol Number: 1.0 | Start Date*: 2019-01-21 | |||||||||||
Sponsor Name:Abteilung für Neurologie der Medizinischen Universität Innsbruck | |||||||||||||
Full Title: Oxytocin and social attention in healthy controls and patients with Parkinson's disease. A randomised, double-blind, placebo-controlled, crossover eye tracking study. | |||||||||||||
Medical condition: Social functioning in Parkinson's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.